All
An Expert Discusses PARP Inhibition, Vaccines and Emerging Therapies in Kidney Cancer
November 3rd 2019The field of kidney cancer treatment could soon be expanding thanks to the inclusion of PARP inhibitors, vaccination-based strategies and emerging therapies such as Fotivda (tivozanib), according to research presented at the 2019 Kidney Cancer Research Summit.
What You Need to Know About the FDA's Approval of Zejula
November 1st 2019The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.
Half of Patients With Breast Cancer Say Transportation Costs Are a Challenge to Treatment
October 29th 2019Forty-eight percent of those surveyed by The Pink Fund said the cost of transportation was a barrier to receiving treatment and 60% missed an appointment or were late to one because of transportation issues.